Myriad Genetics Inc (MYGN) stock
Close on Nov 17, 2026Market cap $529.90MP/E –Yield –
Earnings
Myriad Genetics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Myriad Genetics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 22, 2027Expected | – | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 4, 2026after the close | $202.70M | -1.5% | -$0.46 | -$0.11 | Release |
| Q2 FY2026ended Jun 30, 2026 | Jul 30, 2026after the close | $190.70M | -10.5% | -$0.46 | -$0.25 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 5, 2026after the close | $200.40M | +2.2% | -$0.36 | -$0.09 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 23, 2026after the close | $209.80M | -0.6% | -$0.08 | $0.04 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 3, 2025after the close | $205.70M | -3.4% | -$0.29 | $0.00 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 5, 2025after the close | $213.10M | +0.5% | -$3.57 | $0.05 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 6, 2025after the close | $196.00M | -3.0% | $0.00 | -$0.03 | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 24, 2025after the close | $211.00M | +7.1% | -$0.47 | $0.03 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 7, 2024after the close | $213.00M | +11.0% | -$0.24 | $0.06 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 6, 2024after the close | $212.00M | +15.5% | -$0.41 | $0.05 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 7, 2024after the close | $202.00M | +11.5% | -$0.29 | -$0.01 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 27, 2024after the close | $197.00M | +10.8% | -$0.36 | $0.04 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 6, 2023after the close | $191.90M | +22.7% | -$0.75 | -$0.03 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 3, 2023after the close | $183.50M | +2.3% | -$1.42 | -$0.08 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 3, 2023after the close | $181.20M | +9.9% | -$0.67 | -$0.21 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 28, 2023after the close | $177.80M | – | -$0.52 | -$0.12 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 1, 2022before the open | $156.40M | – | -$0.43 | -$0.19 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 4, 2022before the open | $179.30M | – | -$0.18 | $0.04 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 5, 2022before the open | $164.90M | – | -$0.26 | -$0.03 | Release |
| Q4 FY2020ended Jun 30, 2020 | Aug 13, 2020after the close | – | – | – | – | Filing |
| Q3 FY2020ended Mar 31, 2020 | May 5, 2020after the close | – | – | – | – | Filing |
| Q2 FY2020ended Dec 31, 2019 | Feb 6, 2020after the close | – | – | – | – | Filing |
| Q1 FY2020ended Sep 30, 2019 | Nov 4, 2019after the close | – | – | – | – | Filing |
| Q4 FY2019ended Jun 30, 2019 | Aug 13, 2019after the close | – | – | – | – | Filing |
| Q3 FY2019ended Mar 31, 2019 | May 7, 2019after the close | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Myriad Genetics's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| RevenueGAAP | FY2026 | $780.00M – $790.00M | $860.00M – $880.00M | Lowered | Nov 4, 2026 |
| Revenue | FY2026 | $770.00M – $790.00M | $860.00M – $880.00M | Lowered | Jul 30, 2026 |
| Revenuenon-GAAP | FY2026 | $860.00M – $880.00M | – | New | Jan 12, 2026 |
| Adjusted Gross Margin %non-GAAP | FY2026 | 66% – 67% | 68% – 69% | Lowered | Nov 4, 2026 |
| Adjusted Gross Margin %non-GAAP | FY2026 | 66% – 67% | 68% – 69% | Lowered | Jul 30, 2026 |
| Adjusted EBITDAnon-GAAP | FY2026 | $37.00M – $49.00M | $37.00M – $49.00M | Reaffirmed | May 5, 2026 |
| Adjusted EBITDAnon-GAAP | FY2026 | $37.00M – $49.00M | – | New | Feb 23, 2026 |
Guidance vs results
The last range Myriad Genetics gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| Q1 FY2026 | Revenue | $200.00M – $203.00M | $200.40M | Within range |
| Q1 FY2025 | adjusted EPS | -$0.08 – -$0.04 | -$0.03 | Above range |
| Q1 FY2025 | Revenue | $196.00M – $204.00M | $196.00M | Within range |
| Q1 FY2023 | Adjusted EPS | -$0.20 – -$0.18 | -$0.21 | Below range |
| Q1 FY2023 | EPS (GAAP) | -$0.47 – -$0.45 | -$0.67 | Below range |
| Q1 FY2023 | Revenue | $170.00M – $172.00M | $181.20M | Above range |
Guidance history
Every forecast Myriad Genetics put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 4, 2026 | Adjusted Gross Margin % | FY2026 | 66% – 67% | Lowered |
| Nov 4, 2026 | Revenue | FY2026 | $780.00M – $790.00M | Lowered |
| Jul 30, 2026 | Adjusted Gross Margin % | FY2026 | 66% – 67% | Lowered |
| Jul 30, 2026 | Revenue | FY2026 | $770.00M – $790.00M | Lowered |
| May 5, 2026 | Adjusted EBITDA | FY2026 | $37.00M – $49.00M | Reaffirmed |
| May 5, 2026 | Adjusted Gross Margin % | FY2026 | 68% – 69% | Reaffirmed |
| May 5, 2026 | Revenue | FY2026 | $860.00M – $880.00M | New |
| Feb 23, 2026 | Adjusted EBITDA | FY2026 | $37.00M – $49.00M | New |
| Feb 23, 2026 | Adjusted Gross Margin % | FY2026 | 68% – 69% | New |
| Feb 23, 2026 | revenue | Q1 FY2026 | $200.00M – $203.00M | New |
| Feb 23, 2026 | Revenue | FY2026 | $860.00M – $880.00M | New |
| Jan 12, 2026 | Adjusted EBITDA | FY2026 | $37.00M – $49.00M | New |
| Jan 12, 2026 | Adjusted Gross Margin | FY2026 | 68% – 69% | New |
| Jan 12, 2026 | Revenue | FY2026 | $860.00M – $880.00M | New |
| Aug 5, 2025 | Adjusted EPS | FY2025 | -$0.02 – $0.02 | Lowered |
| Aug 5, 2025 | Revenue | FY2025 | $818.00M – $828.00M | Lowered |
| Feb 24, 2025 | Adjusted EBITDA | FY2025 | $25.00M – $35.00M | Reaffirmed |
| Feb 24, 2025 | adjusted EPS | FY2025 | $0.07 – $0.11 | Reaffirmed |
| Feb 24, 2025 | adjusted EPS | Q1 FY2025 | -$0.08 – -$0.04 | New |
| Feb 24, 2025 | Gross margin % | FY2025 | 69.5% – 70.5% | New |
| Feb 24, 2025 | Adjusted OPEX | FY2025 | $575.00M – $595.00M | Reaffirmed |
| Feb 24, 2025 | Revenue | FY2025 | $840.00M – $860.00M | New |
| Feb 24, 2025 | revenue | Q1 FY2025 | $196.00M – $204.00M | New |
| Jan 15, 2025 | Adjusted EBITDA** | FY2025 | $25.00M – $35.00M | New |
| Jan 15, 2025 | Adjusted EPS*** | FY2025 | $0.07 – $0.11 | New |
| Jan 15, 2025 | Gross margin % | FY2025 | 69.5% – 70.5% | New |
| Jan 15, 2025 | Adjusted OPEX | FY2025 | $575.00M – $595.00M | New |
| Jan 15, 2025 | Revenue | FY2025 | $840.00M – $860.00M | New |
| Nov 7, 2024 | Adjusted EBITDA | FY2024 | $34.00M – $39.00M | Raised |
| Nov 7, 2024 | adjusted earnings per share (EPS) | FY2024 | $0.12 – $0.14 | Raised |
| Nov 7, 2024 | Gross margin % | FY2024 | 69.8% – 70.3% | Narrowed |
| Nov 7, 2024 | Adjusted OPEX | FY2024 | $565.00M – $570.00M | Lowered |
| Nov 7, 2024 | Revenue | FY2024 | $837.00M – $843.00M | Raised |
| Aug 6, 2024 | Adjusted EBITDA** | FY2024 | $25.00M – $35.00M | Raised |
| Aug 6, 2024 | Adjusted EPS*** | FY2024 | $0.08 – $0.12 | Raised |
| Aug 6, 2024 | Gross margin % | FY2024 | 70% – 70.5% | Raised |
| Aug 6, 2024 | Adjusted OPEX | FY2024 | $575.00M – $585.00M | Raised |
| Aug 6, 2024 | Revenue | FY2024 | $835.00M – $845.00M | Raised |
| May 7, 2024 | Adjusted EBITDA | FY2024 | $20.00M – $30.00M | Reaffirmed |
| May 7, 2024 | Adjusted EPS | FY2024 | $0.00 – $0.05 | Reaffirmed |
| May 7, 2024 | Gross margin % | FY2024 | 69.5% – 70.5% | New |
| May 7, 2024 | Adjusted OPEX | FY2024 | $572.00M – $582.00M | Reaffirmed |
| May 7, 2024 | Revenue | FY2024 | $820.00M – $840.00M | New |
| Feb 27, 2024 | Adjusted EBITDA | FY2024 | $20.00M – $30.00M | New |
| Feb 27, 2024 | Adjusted EPS | FY2024 | $0.00 – $0.05 | New |
| Feb 27, 2024 | Gross margin % | FY2024 | 69.5% – 70.5% | New |
| Feb 27, 2024 | Adjusted OPEX | FY2024 | $572.00M – $582.00M | New |
| Feb 27, 2024 | Revenue | FY2024 | $820.00M – $840.00M | Raised |
| Jan 16, 2024 | Adjusted EPS | FY2023 | -$0.33 – -$0.28 | Reaffirmed |
| Jan 16, 2024 | Gross margin % | FY2023 | 69% – 70% | New |
| Jan 16, 2024 | Adjusted operating expenses | FY2023 | $548.00M – $553.00M | Reaffirmed |
| Jan 16, 2024 | Total revenue | FY2023 | $747.00M – $753.00M | New |
| Jan 16, 2024 | full-year revenue guidance | FY2024 | $815.00M – $835.00M | Reaffirmed |
| Nov 6, 2023 | Adjusted EPS | FY2023 | -$0.33 – -$0.28 | Narrowed |
| Nov 6, 2023 | GAAP EPS | FY2023 | -$3.15 – -$3.07 | Lowered |
| Nov 6, 2023 | Gross margin % | FY2023 | 69% – 70% | Raised |
| Nov 6, 2023 | Adjusted OPEX | FY2023 | $548.00M – $553.00M | Narrowed |
| Nov 6, 2023 | GAAP OPEX | FY2023 | $774.00M – $779.00M | Raised |
| Nov 6, 2023 | revenue guidance | FY2024 | $815.00M – $835.00M | New |
| Nov 6, 2023 | revenue guidance | FY2023 | $747.00M – $753.00M | Raised |
| Aug 3, 2023 | Adjusted EPS | FY2023 | -$0.36 – -$0.24 | Reaffirmed |
| Aug 3, 2023 | GAAP EPS | FY2023 | -$2.75 – -$2.60 | Lowered |
| Aug 3, 2023 | Gross margin % | FY2023 | 68% – 70% | Reaffirmed |
| Aug 3, 2023 | Adjusted OPEX | FY2023 | $535.00M – $555.00M | Reaffirmed |
| Aug 3, 2023 | GAAP OPEX | FY2023 | $722.00M – $742.00M | Raised |
| Aug 3, 2023 | Revenue | FY2023 | $730.00M – $750.00M | Reaffirmed |
| May 3, 2023 | Adjusted EPS | FY2023 | -$0.36 – -$0.24 | Narrowed |
| May 3, 2023 | GAAP EPS | FY2023 | -$1.77 – -$1.62 | Lowered |
| May 3, 2023 | Gross margin % | FY2023 | 68% – 70% | Reaffirmed |
| May 3, 2023 | GAAP OPEX | FY2023 | $642.00M – $662.00M | Raised |
| May 3, 2023 | Adjusted OPEX | FY2023 | $535.00M – $555.00M | Raised |
| May 3, 2023 | Revenue | FY2023 | $730.00M – $750.00M | Raised |
| Feb 28, 2023 | Adjusted EPS | Q1 FY2023 | -$0.20 – -$0.18 | New |
| Feb 28, 2023 | Adjusted EPS | FY2023 | -$0.40 – -$0.20 | New |
| Feb 28, 2023 | GAAP EPS | Q1 FY2023 | -$0.47 – -$0.45 | New |
| Feb 28, 2023 | GAAP EPS | FY2023 | -$1.43 – -$1.23 | New |
| Feb 28, 2023 | Gross margin % | FY2023 | 68% – 70% | New |
| Feb 28, 2023 | Gross margin % | Q1 FY2023 | 68% | New |
| Feb 28, 2023 | Adjusted OPEX | Q1 FY2023 | $138.00M – $140.00M | New |
| Feb 28, 2023 | Adjusted OPEX | FY2023 | $530.00M – $550.00M | New |
| Feb 28, 2023 | GAAP OPEX | FY2023 | $628.00M – $648.00M | New |
| Feb 28, 2023 | GAAP OPEX | Q1 FY2023 | $165.00M – $167.00M | New |
| Feb 28, 2023 | Revenue | Q1 FY2023 | $170.00M – $172.00M | New |
| Feb 28, 2023 | Revenue | FY2023 | $720.00M – $750.00M | New |
| Nov 1, 2022 | Earnings (Loss) Per Share | FY2022 | -$0.35 – -$0.30 | Lowered |
| Nov 1, 2022 | Earnings (Loss) Per Share | FY2022 | -$1.35 – -$1.30 | Lowered |
| Nov 1, 2022 | Operating Expenses | FY2022 | $504.00M – $506.00M | Raised |
| Nov 1, 2022 | Operating Expenses | FY2022 | $599.00M – $601.00M | Raised |
| Nov 1, 2022 | Revenue | FY2022 | $668.00M – $672.00M | Lowered |
| Aug 4, 2022 | Earnings (Loss) Per Share | FY2022 | -$0.10 – $0.00 | Lowered |
| Aug 4, 2022 | Earnings (Loss) Per Share | FY2022 | -$1.10 – -$1.00 | Lowered |
| Aug 4, 2022 | Gross Margin | FY2022 | 70% – 72% | Reaffirmed |
| Aug 4, 2022 | Operating Expenses | FY2022 | $490.00M – $500.00M | Raised |
| Aug 4, 2022 | Operating Expenses | FY2022 | $585.00M – $595.00M | Raised |
| Aug 4, 2022 | Revenue | FY2022 | $670.00M – $700.00M | Reaffirmed |
| May 5, 2022 | Adjusted EPS | FY2022 | $0.00 – $0.20 | New |
| May 5, 2022 | GAAP EPS | FY2022 | -$0.90 – -$0.70 | New |
| May 5, 2022 | Gross Margins | FY2022 | 70% – 72% | New |
| May 5, 2022 | Adjusted OPEX | FY2022 | $470.00M – $480.00M | New |
| May 5, 2022 | GAAP OPEX | FY2022 | $556.00M – $566.00M | New |
| May 5, 2022 | Revenue | FY2022 | $670.00M – $700.00M | New |
| May 5, 2022 | estimated organic revenue growth | FY2024 | +9% – +12% | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Myriad Genetics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- News
- Results
- Results
- Results
- Results
See a number that looks wrong?